REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Amoxicillin (Primary) ; Amoxicillin/clavulanic acid (Primary) ; Cefuroxime (Primary) ; Ciprofloxacin (Primary) ; Fluconazole (Primary) ; Linezolid (Primary) ; Nitrofurantoin (Primary) ; Pivmecillinam (Primary) ; Sulfamethoxazole (Primary) ; Trimethoprim (Primary)
- Indications Postoperative infections
- Focus Therapeutic Use
- Acronyms REINFORCE
- 09 Jan 2025 Status changed from not yet recruiting to recruiting.
- 02 Dec 2024 New trial record